文献速递炎症性肠病消化内镜

克罗恩病患者透壁愈合与透壁应答评分工具的建立与验证

Development and Validation of a Score to Assess Transmural Healing and Response in Patients With Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-06-20

DEVISE-CD项目基于两个回顾性队列(274例和224例)和一个多中心前瞻性验证队列(46例)构建并验证了改良Clermont评分(C评分),用于评估克罗恩病透壁愈合(TH)和透壁应答(TR)。C评分由肠壁厚度、淋巴结增大和溃疡计算得出,TH、TR50或TR25均与较低的肠管损伤进展风险相关,前瞻性队列中抗TNF治疗12周后达到TH、TR50或TR25者1年无激素临床缓解率更高。

要点

  • C评分=0.2×(肠壁厚度-3mm)+1.5×淋巴结增大+2×溃疡,用于评估透壁愈合与应答。
  • 回顾性队列中TH(C评分<0.5)与肠管损伤进展风险降低相关(aHR 0.15)。
  • 前瞻性队列中抗TNF治疗12周后达到TH者1年无激素缓解率更高(OR 4.6)。

核心结论

  • C评分是经过验证、可靠且易于使用的工具,可用于评估克罗恩病患者的透壁愈合和透壁应答。

研究设计与样本

  • DEVISE-CD项目包含2个回顾性队列(开发阶段274例、验证阶段224例克罗恩病患者)和1个多中心前瞻性验证队列(46例患者)。
  • 采用逐步法构建改良Clermont评分(C评分)。
  • 回顾性队列主要终点为肠管损伤进展时间,前瞻性验证队列主要终点为1年时粪钙卫蛋白<250的无激素临床缓解。

主要发现

  • 水肿、溃疡、对比剂增强、弥散加权高信号、脂肪爬行、肠壁增厚(>3mm)和淋巴结增大与肠管损伤进展风险较高相关(P<.01)。
  • 水肿、弥散加权高信号、钆对比剂增强后强化和肠壁增厚高度共存(>95%)且共线(P<.0001)。
  • 肠壁厚度对治疗后的变化敏感性最高(标准化均数差=0.30±1.0;P=.001)。
  • 开发与验证队列中,TH(C评分<0.5;HR 0.28 [0.13-0.63];P=.002;aHR 0.15 [0.04-0.53];P=.003)、TR50(C评分下降50%;HR 0.30 [0.15-0.63];P=.001;aHR 0.36 [0.14-0.88];P=.025)或TR25(C评分下降25%;HR 0.37 [0.19-0.71];P=.003;aHR 0.46 [0.23-0.94];P=.034)分别与肠管损伤进展风险降低相关。
  • 前瞻性验证队列中,抗肿瘤坏死因子治疗12周后达到TH(OR 4.6 [1.3-15.6];P=.016)、TR50(OR 6.9 [1.8-26.0];P=.008)或TR25(OR 6.0 [1.6-22.3];P=.008)者1年无激素临床缓解率更高。

关键数值与推荐

  • C评分计算公式:0.2×(肠壁厚度-3mm)+1.5×淋巴结增大+2×溃疡。
  • 透壁愈合定义为C评分<0.5。
  • TR50定义为C评分下降50%,TR25定义为C评分下降25%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Because transmural healing (TH) could be the best therapeutic target in Crohn's disease (CD), we aimed to build and validate a score to assess TH and transmural response (TR), and to confirm their association with favorable CD outcomes. METHODS: DEVISE-CD project encompassed 2 retrospective cohorts (274 and 224 patients with CD for development and validation phase, retrospectively) and 1 multicenter prospective validation cohort (N = 46 patients). A step-by-step process was used to build the modified Clermont score (C-score). The primary end points were time to bowel damage progression, and steroid-free clinical remission with fecal calprotectin <250 at 1 year for retrospective and prospective validation cohorts, respectively. RESULTS: Edema, ulcer, contrast enhancement, diffusion-weighted hyperintensity, fat wrapping, bowel thickening (>3 mm), and enlarged lymph nodes were associated to higher risk of bowel damage progression (P < .01). Edema, diffusion-weighted hyperintensity, post-gadolinium contrast enhancement, and bowel thickening were highly coexistent (>95%) and collinear (P < .0001). Bowel thickness had the highest sensitivity to change after treatment (standardized mean difference = 0.30 ± 1.0; P = .001). C-score was calculated as 0.2x(bowel thickness-3mm) + 1.5x enlarged lymph nodes + 2x ulcer. TH (C-score <0.5; hazard ratio [HR], 0.28 [0.13-0.63]; P = .002; adjusted HR [aHR], 0.15 [0.04-0.53]; P = .003), TR50 (50% decrease of C-score; HR, 0.30 [0.15-0.63]; P = .001; aHR, 0.36 [0.14-0.88]; P = .025), or TR25 (25% decrease of C-score; HR, 0.37 [0.19-0.71]; P = .003; aHR, 0.46 [0.23-0.94]; P = .034) prevented bowel damage progression in development and validation cohorts, respectively. In the prospective validation cohort, achieving TH (OR, 4.6 [1.3-15.6]; P = .016), TR50 (OR, 6.9 [1.8-26.0]; P = .008), or TR25 (OR, 6.0 [1.6-22.3]; P = .008) after 12 weeks of anti-tumor necrosis factor therapy led to higher rate of corticosteroid-free remission at 1 year. CONCLUSIONS: C-score is a validated, reliable, and easy-to-use tool to assess TH and TR in patients with CD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Buisson A, Junda J, Vignette J, et al. Development and Validation of a Score to Assess Transmural Healing and Response in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024. PMID: 38908734. doi:10.1016/j.cgh.2024.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。